[1] |
Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994) [J]. Arch Intern Med, 2002, 162(12): 1401-1408.
|
[2] |
Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure [J]. J Am Coll Cardiol, 2003, 42(11): 1933-1940.
|
[3] |
Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline [J]. Ann Intern Med, 2013, 158(11): 825-830.
|
[4] |
Caldararu CD, Tarta DI, Gliga ML, et al. Comparative analysis of hepcidin-25 and inflammatory markers in patients with chronic kidney disease with and without anemia [J]. Acta Med Marisiensis, 2017, 63(3): 10-14.
|
[5] |
Zadrazil J, Horak P. Pathophysiology of anemia in chronic kidney diseases: a review [J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2015, 159(2): 197-202.
|
[6] |
Bataille S, Pelletier M, Sallee M, et al. Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients [J]. BMC Nephrol, 2017, 18(1): 251.
|
[7] |
Toft G, Heide-Jorgensen U, van Haalen H, et al. Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study [J]. J Nephrol, 2020, 33(1): 147-156.
|
[8] |
Mukhopadhyay P, Sinha U, Banerjee J, et al. The effects in correction of anaemia in chronic kidney disease with erythropoietin therapy--preference to cardiovascular, neurologic and general well-being of patients from a tertiary care centre [J]. J Indian Med Assoc, 2012, 110(12): 885-888.
|
[9] |
Rao M, Pereira BJ. Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease [J]. Kidney Int, 2005, 68(4): 1432-1438.
|
[10] |
中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志,2021, 101(20): 1463-1502.
|
[11] |
Zhou QG, Jiang JP, Wu SJ, et al. Current pattern of Chinese dialysis units: a cohort study in a representative sample of units [J]. Chin Med J (Engl), 2012, 125(19): 3434-3439.
|
[12] |
Perlman RL, Zhao J, Fuller DS, et al. International anemia prevalence and management in peritoneal dialysis patients [J]. Perit Dial Int, 2019, 39(6): 539-546.
|
[13] |
Auerbach M, Henry D, Derman RJ, et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial [J]. Am J Hematol, 2019, 94(9): 1007-1014.
|
[14] |
Locatelli F, Barany P, Covic A, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement [J]. Nephrol Dial Transplant, 2013, 28(6): 1346-1359.
|
[15] |
田延红,田娜,张倩,等. 影响腹膜透析患者血红蛋白水平达标的相关因素分析[J]. 中国血液净化,2020, 19(12): 811-815.
|
[16] |
余少斌,周姣姣,付平,等. 持续性非卧床腹膜透析患者血红蛋白水平分析及相关因素探讨[J]. 中国中西医结合肾病杂志,2016, 17(8): 695-697.
|
[17] |
Meytes D, Bogin E, Ma A, et al. Effect of parathyroid hormone on erythropoiesis [J]. J Clin Invest, 1981, 67(5): 1263-1269.
|
[18] |
Tanaka M, Komaba H, Fukagawa M. Emerging association between parathyroid hormone and anemia in hemodialysis patients [J]. Ther Apher Dial, 2018, 22(3): 242-245.
|
[19] |
Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach [J]. J Am Soc Nephrol, 2004, 15(Suppl 1): S21-S24.
|
[20] |
Mpio I, Boumendjel N, Karaaslan H, et al. Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot study [J]. Nephrol Ther, 2011, 7(4): 229-236.
|
[21] |
Sikole A. Pathogenesis of anemia in hyperparathyroidism [J]. Med Hypotheses, 2000, 54(2): 236-238.
|
[22] |
De Keukeleire S, Muylle K, Tsoumalis G, et al. Primary hyperparathyroidism associated to thrombocytopenia: an issue to consider? [J]. Clin Cases Miner Bone Metab, 2017, 14(1): 97-100.
|
[23] |
Boxer M, Ellman L, Geller R, et al. Anemia in primary hyperparathyroidism [J]. Arch Intern Med, 1977, 137(5): 588-593.
|
[24] |
Kalantar ZK, McAllister CJ, Lehn RS, et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients [J]. Am J Kidney Dis, 2003, 42(4): 761-773.
|
[25] |
Bross R, Zitterkoph J, Pithia J, et al. Association of serum total iron-binding capacity and its changes over time with nutritional and clinical outcomes in hemodialysis patients [J]. Am J Nephrol, 2009, 29(6): 571-581.
|
[26] |
Xiaoyan J, Rongyi C, Xuesen C, et al. The difference of T cell phenotypes in end stage renal disease patients under different dialysis modality [J]. BMC Nephrol, 2019, 20(1): 301.
|